Fund
Polar Capital Healthcare Opportunities I Inc
A fund to invest in growing global demand for healthcare.
Last Updated
09 December 2025
Assets Under Management
1 Year Return
5 Year Annualised Return
Key Information
ISIN
IE00B3K93X10
Inception Date
01 April 2009
Annual Reporting Charge
Ongoing Cost
1.10%
Management Fee
1.00%
12 Month Yield
0.00%
Source: Morningstar
Past performance is not a reliable indicator of future results
Performance
Cumulative Performance (%)
| YTD | 1Mo | 3Mo | 1Yr | 3Yr Ann. | 5Yr Ann. | SI | |
|---|---|---|---|---|---|---|---|
| Total Return | -0.11% | -2.62% | 4.02% | 20.52% | 12.72% | 6.85% | 14.19% |
As at last close.
Portfolio
Type
| Equity | 99.80% | |
| Mutual | 0.15% | |
| Cash | 0.06% |
Sectors
| Healthcare | 100.00% |
Countries
| United States | 40.23% | |
| Denmark | 10.66% | |
| India | 7.47% | |
| Belgium | 7.29% | |
| Germany | 6.24% | |
| Japan | 4.85% | |
| Israel | 4.66% | |
| Sweden | 3.45% | |
| Switzerland | 2.77% | |
| Other | 12.38% |
Top Holdings
| Name | Type | Weight |
|---|---|---|
| Eli Lilly and Co | Equity | 9.59% |
| UCB SA | Equity | 7.27% |
| argenx SE | Equity | 5.95% |
| Zealand Pharma AS | Equity | 4.66% |
| Teva Pharmaceutical Industries Ltd ADR | Equity | 4.65% |
| Fresenius SE & Co KGaA | Equity | 3.88% |
| Chugai Pharmaceutical Co Ltd | Equity | 3.50% |
| Boston Scientific Corp | Equity | 3.42% |
| Cytokinetics Inc | Equity | 3.25% |
| Ascendis Pharma AS ADR | Equity | 3.04% |
As at 30 Nov 2025
